PON1-192 phenotype and genotype assessments in 918 subjects of the Stanislas cohort study

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 4, 2003, Pages 535-540

  Vincent Viry, Monique ^a   Sass, Catherine ^a   Bastien, Sabine ^a   Aguillon, Dominique ^a   Siest, Gérard ^a   Visvikis, Sophie ^a  

^a Centre de Medecine Preventive   (France)

Author keywords

Arylesterase activity; Factors of variation; Paraoxonase activity; PON1 192 genotype (Gln Arg); PON1 192 phenotype

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; ORAL CONTRACEPTIVE AGENT; SODIUM CHLORIDE;

ADOLESCENT; ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; ENZYME ACTIVATION; ENZYME ACTIVITY; FAMILY; FEMALE; GENDER; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL CONTRACEPTION; POPULATION RESEARCH; PRIORITY JOURNAL; REFERENCE VALUE; SMOKING; TOBACCO;

ADOLESCENT; ADULT; ARYLDIALKYLPHOSPHATASE; BLOOD GLUCOSE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; ESTERASES; FASTING; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PARAOXON; PHENOTYPE; POLYMORPHISM, GENETIC; RISK FACTORS; SMOKING; SODIUM CHLORIDE;

NICOTIANA TABACUM;

EID: 0037721384     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.081     Document Type: Article

References (52)

1. Erdös EG, Debay CR, Westerman MP. Arylesterases in blood: effect of calcium and inhibitors. Biochem Pharmacol 1960; 5:173-86.
2. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286:152-4.
3. Laplaud PM, Dantoine T, Chapman MJ. Paraoxonase as a risk marker for cardiovascular disease: facts and hypotheses. Clin Chem Lab Med 1998; 36:431-41.
4. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W, editor. Pharmocogenetics of drug metabolism [review]. New York: Pergamon Press, 1992:51-91.
5. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86:193-9.
6. Mackness MI, Durrington PN. HDL, its enzymes and its potential to influence lipid peroxidation [review]. Atherosclerosis 1995; 115:243-53.
7. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96:2882-91.
8. Ross R. Atherosclerosis - an inflammatory disease [review]. N Engl J Med 1999; 340:115-26.
9. Geldmacher-von-Mallinckrodt M, Lindorf HH, Petenyi M, Flügel M, Fisher T, Hiller T. Genetically determined polymorphism of human serum paraoxonase. Humangenetik 1973; 17:331-5.
10. Diepgen L, Geldmacher-von-Mallinckrodt M. Interethnic differences in the detoxification of organophosphates. Arch Toxicol 1992; S9:154-8.
11. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15:1812-8.
12. Eiberg H, Mohr J, Schmiegelow K. Linkage relationships of paraoxonase (PON) with other markers: indication of PON-cystic fibrosis synteny. Clin Genet 1985; 28:265-71.
13. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3: 73-6.
14. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52: 598-608.
15. Blatter-Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. J Clin Invest 1997; 99:62-6.
16. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/aryl-esterase gene (PON1) is one member of a multigene family. Genomics 1996; 33:498-507.
17. Diaz MN, Frei B, Vita JA, Keaney Jr JF. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337:408-16.
18. Ridker PM. Inflammation, atherosclerosis, and cardiovascular risk: an epidemiologic view [review]. Blood Coagul Fibrinolysis 1999; 10 Suppl 1:S9-12.
19. Cheng S, Grow MA, Pallaud C, Klitz W, Erlich HA, Visvikis S, et al. A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res 1999; 9: 936-49.
20. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86:193-9.
21. Paragh G, Balla P, Katona E, Seres I, Egerhazi A, Degrell I. Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia. Eur Arch Psychiatry Clin Neurosci 2002; 252:63-7.
22. McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem 1986; 32:671-3.
23. Secchiero S, Mussap M, Zaninotto M, Bertorelle R, Burlina A. Serum arylesterase (paraoxo-nase) activity following myocardial infarction. Clin Chim Acta 1989; 183:71-5.
24. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a riskfactor for coronary artery disease. J Clin Invest 1995; 96:3005-8.
25. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol 1997; 17:1067-73.
26. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, et al. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 1997; 17:3565-9.
27. Odawara M, Tachi Y, Yamashita K. Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82:2257-60.
28. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19:330-5.
29. Bonafe M, Marchegiani F, Cardelli M, Olivieri F, Cavallone L, Giovagnetti S, et al. Genetic analysis of paraoxonase (PON1) locus reveals an increased frequency of Arg 192 allele in centenarians. Eur J Hum Genet 2002; 10:292-6.
30. Yongjing X, Gueguen R, Vincent-Viry M, Siest G, Visvikis S. Effect of six candidate genes on early aging in a French population. Aging Clin Experiment Res. In press.
31. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis [review]. Arterioscler Thromb Vasc Biol 2001; 21:473-80.
32. Antikainen M, Murtomaki S, Syvanne M, Pahlman R, Tahvanainen E, Jauhiainen M, et al. The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996; 98:883-5.
33. Herrmann SM, Blanc H, Poirier O, Arveiler D, Luc G, Evans A, et al. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study. Atherosclerosis 1996; 126:299-303.
34. Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige N, et al. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol. 1996; 57:69-73.
35. Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, et al. The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 1998; 18:1611-6.
36. Cao H, Girard-Globa A, Serusclat A, Bernard S, Bondon P, Picard S, et al. Lack of association between carotid intimamedia thickness and paraoxonase gene polymorphism in non-insulin dependent diabetes mellitus. Atherosclerosis. 1998; 138:361-6.
37. Cao H, Girard-Globa A, Berthezene F, Moulin P. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism. J Lipid Res 1999; 40:133-9.
38. Pallaud C, Sass C, Zannad F, Siest G, Visvikis S. APOC3, CETP, fibrinogen, and MTHFR are genetic determinants of carotid intima-media thickness in healthy men (the Stanislas cohort). Clin Genet 2001; 59:316-24.
39. Durrington PN, Mackness B, Mackness MI. The hunt for nutritional and pharmacological modulators of paraoxonase. Arterioscler Thromb Vasc Biol 2002; 22:1248-50.
40. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, et al. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 2002; 22:1329-33.
41. Vincent-Viry M, Marangon K, Limasset G, Gueguen R, Herbeth B, Artur Y, et al. Paraoxonase polymorphism in healthy families belonging to the Stanislas cohort: description and influence of environmental factors. Comptes-Rendus du Ixième Colloque International de Pont à Mousson, Eurobiologie, 29 Sep-3 Oct 1996, 1997:149-53.
42. James RW, Leviev I, Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 2000; 101:2252-7.
43. van der Gaag MS, van Tol A, Scheek LM, James RW, Urgert R, Schaafsma G, et al. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis 1999; 147:405-10.
44. Siest G, Visvikis S, Herbeth B, Gueguen R, Vincent-Viry M, Sass C, et al. Objectives, design and recruitment of a familial and longitudinal cohort for studying gene-environment interactions in the field of cardiovascular risk: the Stanislas cohort. Clin Chem Lab Med 1998; 36:35-42.
45. Eckerson H, Wyte C, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35:1126-38.
46. Miller SA, Dykes DD, Polesky HFA. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 1988; 16:1215.
47. Cheng S, Pallaud C, Grow MA, Scharf SJ, Erlich HA, Klitz W, et al. A multilocus genotyping assay for cardiovascular disease. Clin Chem Lab Med 1998; 36:561-6.
48. Jarvik G, Rosek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1 (192) or PON1 (55) genotype. Arterioscler Thromb Vasc Biol 2000; 20:2441-7.
49. Richter R, Furlong CE. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 1999; 9:745-53.
50. Nishio E, Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun 1997; 236:289-93.
51. Saha N, Roy AC, Teo SH, Tay JSH, Ratmann SS. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet 1991; 40:277-82.
52. Hegele RA, Brunt JH, Connelly PW. Multiple genetic determinants of variation of plasma lipoproteins in Alberta Hutterites. Arterioscler Thromb Vasc Biol. 1995; 15:861-71.